Articles

carotid artery stenting, outcomes, JACC, Beau Hawkins, Robert Yeh, CARE Registry

Hospitals performing carotid artery stenting vary considerably in rates of in-hospital stroke or death, according to a study published in JACC: Cardiovascular Interventions. Those...

CardiAQ, Edwards, acquire, acquisition, Fortis, TMVI, mitral valve replacement

Edwards Lifesciences Corp. announced that it has agreed to acquire CardiAQ Valve Technologies Inc., a privately held company and developer of a transcatheter mitral valve replacement (TMVR) system...

sentraheart lariet, LAA occlusion, FDA safety alert

The U.S. Food and Drug Administration (FDA) is alerting healthcare providers and patients of reports of patient deaths and other serious adverse events associated with the use of the Lariat Suture...

21st Century Cures Act, H.R. 6, HR-6, HR 6, medical device innovation

The U.S. House of Representatives July 10 passed its version of the 21st Century Cures Act (H.R. 6), designed to improve the U.S. healthcare innovation infrastructure. It was approved in a...

platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB

Researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles could one day be used to control excessive bleeding following traumatic injury...

wearable sensors, Verizon, fitness trackers, smart watches

Wearable sensors are expected to play a big role in healthcare in the coming years, according to Verizon, as data from these devices are integrated into patient electronic medical records. They...

Opsens Medical, FFR, OptoWire, OptoMonitor, FDA, fractional flow reserve

Opsens Inc. announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the OptoWire and OptoMonitor, its products developed to measure fractional flow reserve (FFR). This...

St. Jude Medical, OCT, ILUMIEN III, IVUS, angiography, PCI

St. Jude Medical, Inc. announced the launch of the ILUMIEN III clinical trial on June 30. ILUMIEN III is a prospective, international, randomized trial evaluating the clinical benefits of the...

Sorin S.p.A. and Cyberonics Inc. unveiled LivaNova as the name of their combined company, effective at the close of their proposed merger.

C.R. Bard, LEVANT 2 results, Lutonix 035 DCB, drug coated balloon, PTA

C.R. Bard Inc. announced the publication of results from the LEVANT 2 study in the June 24, 2015, online issue of The New England Journal of Medicine. Results from LEVANT 2 demonstrated...